Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well explained Raf
Why didn’t healthnet change their coverage for V & GV now that they know !???
Their reply is full of nonsense
May is a decisive month for Amarin !
Fingers crossed
Raf, undoubtedly this is due to your pressure ??
I see the Q1 results as being rather positive.
If i am not mistaken this is the first quarter where the (EPS) is not negative under GAAP measures, noting that Q1 is always the slowest and weakest.
- Amarin Q1 Non-GAAP EPS of $0.03 beats by $0.07;
- GAAP EPS of $0.00 beats by $0.05.
- Revenue of $142.17M (-8.3% Y/Y) misses by $4.93M.
Not that bad results
Sleven
I totally agree with you... Generics are getting more and more desperate!
That’s good :)
Well done Raf !
Who think that it is possible for amarin to ends 2021 with $800 Mio in revenues ???
- 20% increase in yoy sales taking into accounts the subsiding of Covid and the supply constraints of generics.
- around $50 Mio from sales in Europe
- around $10 Mio revenue from Canada, Middle East and ROW....
Might be a long shot but doable ??
Capt
My vote for question number 10
And i suggest to add the following question : The current stock price does not reflect the financial status of a debt free company with around $500 Mio in cash or equivalents, and a drug with multi billion dollars sales potential. What is the management’s strategy on the short term to deal with the company’s weak stock price performance?
Thank you for putting the list of questions
Amarin AMRN announced today that it will host a conference call with members of senior management to discuss the company's first quarter 2021 financial results and provide an operational update on Thursday, April 29, 2021, at 7:30 a.m. ET.
Not a lawyer but based on common sense and logic i believe amarin’s briefs are strong .
Any opinion from lawyers ?
REUTERS “Resuming the use of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine in the United States will require clear guidelines for the medical community on how to best treat patients that develop a rare type of blood clot, as well as alerting vaccine recipients to be aware of the telltale symptoms, according to heart doctors and other medical experts”
Can Vascepa be the solution ???
Thank you Raf... +ve numbers
Raf ... waiting for ur scripts :) :) :)
I have a feeling today is going to be a good day for Amarin !
But at the end who knows.... those are my feelings that keeps on getting me into trouble !
Ex 77
Thank you Marjac for the detailed reply !
Marjac
Do you see the non response as a good sign or bad?
Thxx
FFS do you believe we might see the $4 again?
Captbeer... accordingly sales will be around $158-160 Mio!
Not too bad given the Covid effect
Thank you gg
Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $19 price target on Amarin after the company announced that Karim Mikhail would succeed John Thero as CEO later this year. The Street was surprised by the announcement, the analyst tells investors in a research note, but she believes that his deep commercial expertise will facilitate Amarin's continued growth, especially ahead of VAZKEPA's E.U. launch in Q3 of this year.
A question for lawyers
Can the SC decide on the 16th to take amarin’s case even if Hikma did not file its reply,
And consequently consider the reply as part of the court’s review of the case?
Thxx
A question for lawyers
Can the SC decide on the 16th to take amarin’s case even if Hikma did not file its reply,
And consequently consider the reply as part of the court’s review of the case?
Thxx
John Thero to Retire as President and CEO on August 1, 2021
Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor
Biotech
What does this chart mean?
Thank you Marjac !
Marjac
When do you expect to hear from judge Du?
A big applaud to you all !!
May truth prevail and may the disgruntled shareholders prevail and come out with a miracle in the world of law !
Bravo Marjac !
Excellent Marjac !
Now that major insurance companies are dropping GV, a serious question arises; what’s the interest of Hikma in a market of 10s of millions of $ only while facing several litigations due to her actions???
What are the chances that the SC accepts Hikma’s request for a delay ?
Could not understand what Hikma is hinting too when they mentioned that Amarin waited till Feb. to file the case to the SC or when they mentioned that amarin did not request an injunction on generics vascepa !
Anyone can help?
The negative mood on the board today is depressing, for no valid reasons, i mean did you really believe that amarin will be able to initiate sales in Europe the next day after the approval???? Even bigger companies won’t be able to execute this.
Also you are just assuming that the company will have a secondary offering and started blaming the management without even having a real indication that this is happening !
We are at our worst situation, things can only improve, even if it will take some time.
But who knows, this is just the humble opinion of someone who believes that better days are ahead of us.
Ex77
Thxx North
Marjac
When is the due date for your reply to Hikma’s bullshit ?
Thank u
Thank you Capt
Capt i believe we are very close to the numbers of Q1 2020